ELAN — Deep Dive

Deep Dive Ticker Tape
5 min read

ELAN — Deep Dive

3 tickers referenced · published Jun 4, 2026

Article published Jun 4, 2026. Prices below use latest available snapshots.

ELAN $23.61 -8.6% 30d ZTS $72.97 -4.7% 30d PAHC $34.63 +4.0% 30d

Thesis: Elanco is the cleanest livestock-disease/screwworm vehicle — ~47% farm-animal (cattle ~23% of revenue) + poultry/swine cross-protein hedge, +15% rev growth, raised FY26 guide, analyst strong_buy — but already bid (RSI 64, near highs) at a full multiple (fwd P/E 20.7 vs ZTS 10.8 / PAHC 9.9); screwworm products are immaterial line items, so size on the cattle-parasiticide demand pull, not the catalyst

Setup

Tape 2026-06-04 (code-computed, summary CLI): $25.12, RSI 64, +11.6% 30d, +2.8% 3m, −9.4% from 52wk high. Already bid, near the top of its range — not a deep-value entry. Analyst mean target $29.78 (14 analysts, strong_buy).

  • Entry zone: ~$22.00–23.50 (a pullback toward the rising SMA / prior base — better risk/reward than chasing at RSI 64 near highs). Or a small starter now with adds on the escalation tell.
  • Stop: ~$19.00 (below the recent consolidation base; the thesis is wrong if it loses the base).
  • Target: base ~$30 (analyst mean); bull ~$34–35 on a screwworm-escalation re-rate + the deleveraging-to-clean-EPS story holding. Sized as a medium-conviction position, not a swing.

Why not a chase here: the catalyst (screwworm) is a narrative/sentiment tailwind on top of an already-working cattle+pet story — it is not material to the financials (see below). At RSI 64 near highs you're paying up for a thesis the tape has partly priced; the asymmetric add is on the out-of-zone detection escalation tell, not at spot.

Business mix (Q1 2026, from the 10-Q / 8-K)

Revenue $1,371M, +15% YoY (rev growth +14.9%):

  • Pet Health $710M (51.8%) — the bigger half; secular, recession-resistant companion-animal spend (Elanco's own survey: ~95% of owners won't cut pet-health spend). Advantage/Seresto/Credelio.
  • Farm Animal $642M (46.8%) — Cattle $316M (~23% of total), Poultry $230M (~17%), Swine $96M (~7%).
  • Contract Mfg/Other $19M.
  • FY2026 guidance raised to $5.01–5.08B (Q1 beat + raise).

Two load-bearing reads from the mix:

  1. Cattle is 23% of revenue ($1.26B/yr) — meaningful but not dominant. The screwworm/NWS parasiticide tailwind hits this segment; both ELAN and ZTS earnings already cite "expanded targeted parasiticide use in response to New World Screwworm." But the named screwworm products (Negasunt™/Tanidil™) do not appear as a line item in the Q1 disclosures — confirming they are immaterial as products. Size the thesis on cattle-segment + herd-health demand pull, not the catalyst SKU.
  2. Poultry ($230M) + Swine ($96M) = a built-in cross-protein hedge. If the beef shock pushes substitution toward chicken/pork (the protein-rotation thesis), ELAN's poultry/swine animal-health segments benefit too. ELAN wins whichever protein wins — a structural advantage over a pure-beef play, and over the crushed poultry/plant-based equities.

Financials (Massive, 8 quarters — data/stocks/ELAN/massive/)

  • Q1 2026: Revenue $1.37B, Gross $0.79B, Op income $0.09B (op margin +12.3% +6.4% — correction 2026-08-03: $87M / $1,371M = 6.35%; the TTM operating margin is −4.0%)**, Net $0.06B, EPS $0.11 — back to positive after loss quarters in 2025 (Q4'25 EPS −$0.56 / Net −$0.28B; Q3'25 −$0.07). TTM revenue ≈ $4.9B; TTM net is still slightly negative (the Q4'25 charge), so there's no clean trailing P/E — the story is the forward turn.
  • Balance sheet (Q1'26): long-term debt $3.74B (Massive) / total debt $4.30B incl. leases (market data), cash $0.43B → net debt ~$3.9B; total equity $6.5B; debt/equity ~66%. This is the post-Bayer-Animal-Health (2020, ~$7.6B) leverage — the historical overhang — but D/E 66% is far healthier than ZTS's 286%, and it's deleveraging as EBITDA recovers.

Valuation vs peers (2026-06-04)

ELAN ZTS PAHC
Mkt cap / EV $12.5B / $16.1B $33.6B / $39.8B $1.3B / $2.0B
Fwd P/E 20.7 10.8 9.9
P/S (TTM) 2.56 3.52 0.90
EV/EBITDA 16.6 9.8 8.5
Op margin 12.3% 6.4% (Q1'26) / −4.0% TTM (corrected 2026-08-03) 36.6% 12.6%
Net margin −4.9% (TTM) 28.0% 6.3%
Rev growth +14.9% +2.9% +10.3%
Analyst strong_buy, $29.78 buy, $124.59 $45.60

Read: ELAN is the growth name and is priced like one — richest multiple of the three (fwd 20.7, EV/EBITDA 16.6) on the thinnest net margin (debt/amortization drag). You're paying up for +15% growth + the deleveraging-to-clean-EPS turn + the livestock+pet franchise. ZTS is quality-at-a-discount (28% net, fwd 10.8 after the −53% drawdown) but its weakness is company-specific and it is not the screwworm catalyst trade. PAHC is deep-value/livestock-pure (P/S 0.90) but tiny and washed out — the contrarian escalation-optionality name, not the core.

Bull case

  • The one clean, on-thesis vehicle for livestock-disease: livestock-weighted farm-animal book
    • the only animal-health name with a named, emergency-authorized NWS product (Negasunt/Tanidil), rev accelerating +15%, raised FY26 guide, insider buying (🟢🟢), analyst strong_buy.
  • Cross-protein hedge (poultry+swine) means ELAN captures the substitution rotation regardless of which protein wins — unlike the crushed poultry/plant-based equities or a pure beef bet.
  • Deleveraging turn: Q1'26 back to positive EPS; if the clean-EPS trajectory holds, the fwd multiple compresses into the growth and the debt overhang narrative fades.
  • Escalation optionality: an out-of-zone screwworm detection re-rates the whole cattle parasiticide demand curve — ELAN is the most direct listed beneficiary.

Bear case

  • Already bid / full multiple: RSI 64 near highs, fwd P/E 20.7 vs peers ~10, only ~mid-teens % to the analyst mean — limited margin of safety; a growth wobble de-rates it fast.
  • The catalyst is immaterial to the P&L: screwworm products aren't a line item; if the cattle parasiticide pull is smaller than the narrative, the stock is just a ~$5B-rev animal-health compounder at a premium price.
  • Debt still ~$3.9B net — a rate or EBITDA stumble re-opens the leverage overhang; net margin is still negative TTM.
  • Pet Health (52%) is the real driver, not cattle — a consumer-spend or GLP-1-for-pets scare (compounded-GLP-1 competition narrative that's hammered ZTS) could hit ELAN's larger half and swamp any farm-animal screwworm tailwind.
  • Macro: the whole protein/animal-health complex is in a drawdown; being early without dispersion (see 2026-06-04-beef-crisis-protein-rotation-complex-map) means you wait.

Catalysts

  • Out-of-zone NWS detection (the alert trigger) — beyond the USDA 20 km infested zone → cattle parasiticide demand re-rate. The asymmetric catalyst.
  • Q2 2026 earnings (~early Aug): cattle-segment growth + whether NWS parasiticide use shows up in the numbers; deleveraging / clean-EPS progress; FY guide.
  • FDA actions on additional NWS treatments (ELAN or peers) — incremental sentiment.
  • Pet Health prints (the larger half) — the real swing factor on the stock.

Sources